Atezolizumab: Phase Ib amended

Roche’s Genentech unit amended an open-label, U.S. Phase Ib trial of IV atezolizumab with and without

Read the full 169 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE